Dual-specificity phosphatase 23 functions as a promising prognostic biomarker in non-small cell lung cancer
- PMID: 39693003
- DOI: 10.1007/s13258-024-01604-9
Dual-specificity phosphatase 23 functions as a promising prognostic biomarker in non-small cell lung cancer
Abstract
Background: The mechanical remodeling of tumor microenvironment is critical for non-small cell lung cancer (NSCLC) progression. Dual-specificity phosphatase 23 (DUSP23) has been previously identified as a mechano-responsive gene, but its role in NSCLC progression remains unknown.
Objective: We aim to elucidate the clinical significance of DUSP23 in NSCLC progression.
Methods: We analyzed the expression of DUSP23 in cancer using polyacrylamide hydrogels designed to mimic the stiffness of normal (soft; ~0.5 kPa) and cancerous (stiff; ~40 kPa) tissues. The prognostic significance of DUSP23 expression in patients was examined using public databases. Additionally, we conducted various cell-based assays and transcriptomic analyses in DUSP23-silenced NSCLC cell lines. A risk score prognosis model was constructed using univariate Cox regression and Kaplan-Meier analysis.
Results: Our findings show that DUSP23 is upregulated in stiff matrices and is highly associated with poor prognosis in patients with solid cancers such as NSCLC and breast cancer. Silencing of DUSP23 resulted in decreased cell proliferation and invasion. Transcriptomic profiling revealed that 182 genes were downregulated, and 230 genes upregulated following DUSP23-depletion. Notably, 182 downregulated genes were enriched in cancer-related pathways, including cell cycle progression and cytoskeleton organization. Through KEGG pathway analysis, we identified 11 cancer-related genes and developed a prognostic risk model. In this model, the high-risk group of NSCLC patients exhibited significantly shorter overall survival compared to low-risk group, based on public datasets.
Conclusion: Our study demonstrates the clinical significance of DUSP23 as a prognostic marker in NSCLC and highlights its potential role of DUSP23 in promoting NSCLC progression.
Keywords: Bioinformatic analysis; DUSP23; NSCLC; Prognostic biomarker; Transcriptome analysis.
© 2024. The Author(s) under exclusive licence to The Genetics Society of Korea.
Conflict of interest statement
Declarations. Conflict of interest: Authors declare no conflicts of interest.
Similar articles
-
RBBP4: A novel diagnostic and prognostic biomarker for non-small-cell lung cancer correlated with autophagic cell death.Cancer Med. 2024 Aug;13(15):e70090. doi: 10.1002/cam4.70090. Cancer Med. 2024. PMID: 39109577 Free PMC article.
-
Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.Am J Physiol Lung Cell Mol Physiol. 2019 May 1;316(5):L918-L933. doi: 10.1152/ajplung.00334.2018. Epub 2019 Jan 10. Am J Physiol Lung Cell Mol Physiol. 2019. PMID: 30628487
-
CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis.BMC Cancer. 2025 Apr 14;25(1):688. doi: 10.1186/s12885-025-14044-9. BMC Cancer. 2025. PMID: 40229784 Free PMC article.
-
Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.BMC Med Genomics. 2020 Aug 14;13(1):112. doi: 10.1186/s12920-020-00762-5. BMC Med Genomics. 2020. PMID: 32795325 Free PMC article.
-
MicroRNA-486: a dual-function biomarker for diagnosis and tumor immune microenvironment characterization in non-small cell lung cancer.BMC Med Genomics. 2025 May 19;18(1):92. doi: 10.1186/s12920-025-02158-9. BMC Med Genomics. 2025. PMID: 40390034 Free PMC article.
References
-
- Bargagli E, Bonti V, Ferrari K, Rosi E, Bindi A, Bartolucci M, Chiara M, Voltolini L (2017) Lung Cancer in patients with severe idiopathic pulmonary fibrosis: critical aspects. Vivo 31:773–777 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical